EyePoint Reports Second Late-Stage Duravyu Study Failure
EyePoint reported a second late-stage study failure for its proposed Duravyu treatment for wet age-related macular degeneration. Its shares fell sharply on Monday.
EyePoint shares plunged Monday after the clinical-stage biopharmaceutical company said a second late-stage study of its proposed Duravyu treatment candidate for wet age-related macular degeneration, or wet AMD, had failed. The shares were recently trading at 57…